Mount Yale Investment Advisors, LLC Crispr Therapeutics Ag Transaction History
Mount Yale Investment Advisors, LLC
- $1.21 Billion
- Q2 2025
A detailed history of Mount Yale Investment Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Mount Yale Investment Advisors, LLC holds 300 shares of CRSP stock, worth $18,591. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300Holding current value
$18,591% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
541Shares Held
68.5MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$631 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$347 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$228 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$203 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$176 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.83B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....